title: Extended-field radiation therapy with whole pelvis radiotherapy and cisplatin chemosensitization in the treatment of IB2-IIIB cervical carcinoma: a retrospective review.
abstract: OBJECTIVE
  This retrospective study evaluated the toxicity of extended-field radiation therapy (EFRT), whole pelvis radiotherapy, and concurrent chemotherapy in patients treated with IB2-IIIB cervical carcinoma.
  
  
  METHODS
  Patients treated with EFRT, whole pelvis radiotherapy, and concurrent chemotherapy were analyzed for toxicity. Median prescribed dose to the whole pelvis was 45 Gy (45-50 Gy). Median prescribed dose to the paraaortic lymph nodes was 45 Gy (36-50). Thirty-five patients received cisplatin chemosensitization at a median dose of 40 mg/m(2) (40-51), with a median of 5 cycles (2-6).
  
  
  RESULTS
  Thirty-six patients were treated, 3 with positive paraaortic lymph nodes. The median follow-up interval was 32 months. Twenty-four patients (66.7%) had no evidence of disease at last follow-up. Thirteen patients (36.1%) had recurrence. Fifteen patients (41.7%) experienced acute grade 3 toxicity.
  
  
  CONCLUSIONS
  Increased toxicity in patients warrants careful patient selection.
authors.affiliation: Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA, USA.
authors.forename: Kari L
authors.initials: KL
authors.lastname: Ring
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Young
authors.forename: Neal E
authors.initials: NE
authors.lastname: Dunlap
authors.forename: Willie A
authors.initials: WA
authors.lastname: Andersen
authors.forename: Bernard F
authors.initials: BF
authors.lastname: Schneider
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy; D000328:Adult; D001918:Brachytherapy / Q000379:methods*; D018196:Carcinoma, Adenosquamous / Q000473:pathology / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D055815:Young Adult
chemical_list: D011838:Radiation-Sensitizing Agents; D002945:Cisplatin